Other groups have identified that CD14+ cells imparted targeted therapy resistance to lung cancer cell lines and that an increasing CD14+ cell presence in the TME is associated with a shorter duration of patient benefit with targeted therapy [34]. The gene discussed is CD14; the disease is lung carcinoma.